Answers are grounded in this paper and cite their sources.
BACKGROUND: Multiple endocrine neoplasia (MEN) syndromes involve tumors in multiple endocrine organs. Distinguishing MEN1 from rarer MEN-like syndromes, including MEN4 caused by pathogenic germline CDKN1B variants, can be challenging. METHODS: We describe four individuals from two families, integrating clinical, biochemical and imaging findings with germline whole-exome sequencing, evolutionary conservation, in silico variant-effect prediction, structural modeling and molecular dynamics. Tumor tissue was unavailable for somatic sequencing or loss-of-heterozygosity analysis. RESULTS: Proband 1, initially suspected of MEN1 because of a nonfunctioning pituitary microadenoma, bilateral adrenal hyperplasia and primary hyperparathyroidism, carried a pathogenic germline CDKN1B frameshift variant, p.Lys96GlnfsTer29. Proband 2 carried the CDKN2C p.Leu107Val variant, classified as a variant of uncertain significance, and had hyperthyroidism, primary hyperaldosteronism, nephrolithiasis, primary hyperparathyroidism, a nonfunctioning pituitary microadenoma and a pancreatic mucinous cystic neoplasm. The variants showed distinct predicted mechanisms. The CDKN1B frameshift preserves the kinase-inhibitory domain but removes the C-terminal regulatory region of p27Kip1 and is predicted to trigger nonsense-mediated decay. In contrast, CDKN2C Leu107 is evolutionarily invariant and buried within the hydrophobic core of ankyrin repeat 4; substitution by valine reduced local hydrophobic packing, consistent with partial destabilization rather than protein loss. The two variant-positive sons of Proband 2 were asymptomatic, and no variant-positive individual carried a MEN1 mutation. CONCLUSIONS: These findings support CDKN1B testing in MEN1-negative patients with MEN features and highlight CDKN2C as a candidate contributor to MEN-like phenotypes. Integrated clinical, genetic, conservation and structural data may support future re-evaluation of p.Leu107Val while preserving its current VUS classification.
No takes yet. Share an insight, caveat, or question.
Papadopoulou‐Marketou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: